| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
5
5
5
4
|
|
Zacks Investment Research
5
(Strong Sell)
|
|
Standard & Poor's
5 / 5 Stars
|
|
TheStreet.com
B+
(Buy)
|
Fund Holdings
According to the prospectus, “The fund invests mainly in large- and mid-capitalization companies whose stocks are considered by an adviser to be undervalued.”
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 2.56 | 2.56 |
| Stocks | 88.62 | 88.62 |
| Bonds | 0.0 | 0.0 |
| Other | 0.0 | 0.0 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 8.81 | 8.81 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 12.31.2012
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 12.31.2012
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Pfizer Inc | PFE | 16.19 | 3.02 |
| Philip Morris International, Inc. | PM | 15.4 | 2.82 |
| JPMorgan Chase & Co | JPM | 10.55 | 2.52 |
| Johnson & Johnson | JNJ | 21.03 | 2.47 |
| American Express Co | AXP | 19.49 | 2.38 |
| Baxter International Inc. | BAX | 4.05 | 2.33 |
| Wells Fargo & Co | WFC | 10.33 | 2.24 |
| Microsoft Corporation | MSFT | 23.36 | 2.21 |
| ConocoPhillips | COP | 4.62 | 2.17 |
| Raytheon Company | RTN | 8.08 | 2.12 |
